Sanuwave's Preliminary Q2 Revenue Slips Year Over Year But Tops Revised Guidance; Stock Up
Sanuwave Health (SNWV) issued a preliminary Q2 2026 revenue outlook of $9.6 to $9.8 million, down about 3% to 5% from $10.1 million in Q2 2025. The estimate is above the company’s revised June 16 guidance of $8.5 to $9.5 million, which it lowered due to market disruption impacting Ultramist capital equipment sales.
How this was made
The 30-second read
Why it matters
The key new datapoint is that preliminary Q2 revenue is expected to exceed the company’s own June 16 guidance reduction, which was attributed to market disruption affecting Ultramist capital equipment sales.
Market read
A guidance-beat versus a recently lowered range can drive short-term repricing, even if the quarter remains slightly weaker year over year.
What to watch
The article does not quantify how much of the beat is timing-related versus structural; traders may wait for full financials to confirm margins and cash flow.
Background
Sanuwave sells patented non-invasive directed-energy systems (Ultramist) used to repair/regenerate skin, musculoskeletal tissue, and vascular structures.
Ticker impact
Sanuwave Health reported preliminary Q2 revenue of $9.6M to $9.8M, above its June 16 revised guidance of $8.5M to $9.5M.
Near-term bias positive, with traders likely to reassess the magnitude of the Ultramist disruption impact on Q2 results.
The article provides specific revenue ranges and explicitly states the preliminary figure exceeds the company’s own revised guidance, which is a direct earnings-risk update rather than a generic recap.
Market effects
Directed-energy medical device names may see read-across on demand durability if Ultramist-related disruption appears less severe than feared.
No specific regional market linkage beyond US small-cap biotech sentiment.
Limited global relevance; the update is company-specific and tied to Ultramist capital equipment sales.
Counterpoint
The revenue is still down year over year (about 3% to 5%), so the beat versus lowered guidance may not signal a true demand recovery.
Key entities
- public_companySanuwave Health, Inc.
Subject of the article, providing preliminary Q2 2026 revenue guidance and explaining the June 16 guidance cut.
- product_systemUltramist
Directed-energy system whose capital equipment sales were cited as disrupted when guidance was lowered on June 16, 2026.
